ARS Pharmaceuticals (SPRY) Debt Ratio (2020 - 2021)
ARS Pharmaceuticals' (SPRY) quarterly Debt Ratio came in at 0.08 in Q4 2021, up 3653.12% year-on-year from 0.0 in Q4 2020, and up 6094.95% quarter-over-quarter from 0.0 in Q1 2021.
ARS Pharmaceuticals (SPRY) Debt Ratio (2020 - 2021) Analysis & Trends
ARS Pharmaceuticals has disclosed Debt Ratio across 2 years of filings, most recently posting 0.08 for Q4 2021.
- Debt Ratio for Q4 2021 came in at 0.08, up 3653.12% year-over-year; the trailing twelve-month figure through Dec 2021 was 0.08 (up 3653.12% YoY), and the FY2021 annual result was 0.08, up 3653.12% from the prior year.
- Debt Ratio came in at 0.08 for Q4 2021 at ARS Pharmaceuticals, up from 0.0 in the prior quarter.
- In the past five years, Debt Ratio ranged from a high of 0.08 in Q4 2021 to a low of 0.0 in Q1 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 0.18 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | ARS Pharmaceuticals | 954.24 Mn | 753.27 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 0.08 |
| Mar 31, 2021 | 0.00 |
| Dec 31, 2020 | 0.00 |